Content Harbour BioMed Collaborates with Insilico for Rapid AI-Driven Antibody Discovery

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel antibody therapeutics in immunology and oncology, has partnered with Insilico Medicine, an AI-driven clinical-stage biotechnology firm. This strategic collaboration aims to accelerate the creation of innovative therapeutic antibodies by leveraging each organization’s unique strengths.

Under the terms of their agreement, Harbour BioMed will contribute its cutting-edge technology platform, proprietary data set, and extensive expertise in antibody development. Insilico Medicine, on the other hand, brings advanced AI capabilities for designing integrated drug discovery and development platforms. Together, they plan to develop next-generation AI-powered applications focused on antibodies.

The collaboration also involves joint efforts in early-stage drug discovery programs targeting novel specific antibodies. By combining Harbour BioMed’s laboratory expertise with Insilico’s AI technology, the companies aim to meet unmet medical needs in immunology, oncology, and neuroscience through innovative therapeutic solutions.

Harbour BioMed has established a robust foundation in antibody research and development supported by its advanced platform, proprietary data set, and extensive knowledge. The company’s Harbour Mice® platform is capable of producing fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats, eliminating the need for additional engineering or humanization processes. The HCAb technology generates unique heavy chain-only antibodies that are about half the size of traditional IgGs, offering significant advantages in next-generation therapies.

With a proven clinical platform recognized globally, Harbour BioMed has engaged its technology across over 250 drug discovery programs in various therapeutic areas, solidifying its leadership role in biotherapeutics. Insilico Medicine boasts an AI-driven pharmaceutical development pipeline of 30 assets since 2021, with ten receiving IND clearance.

In July 2024, Insilico introduced Generative Biologics—a tool for de novo protein engineering designed to accelerate the creation of next-generation biologics. The company plans continuous improvements based on real-world case studies and iterative advancements.

“We are thrilled to collaborate with Harbour BioMed, a leader in antibody discovery and development,” said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. “By integrating advanced machine learning models with our biological expertise, we aim to revolutionize the field by predicting antibody structures, identifying binding sites, and designing more specific, effective, and safe candidates.”

Jingsong Wang, MD, PhD—Founder, Chairman, and CEO of Harbour BioMed—added: “This collaboration marks an exciting opportunity for us. By combining Insilico’s cutting-edge AI technologies with our validated Harbour Mice® platform and deep industry knowledge in antibody discovery and development, we aspire to accelerate the process of discovering new antibodies while enhancing candidate selection.” The ultimate goal is to deliver breakthrough therapies more efficiently.